{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:49:12Z","timestamp":1784029752537,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["R25CA56452"],"award-info":[{"award-number":["R25CA56452"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA118638"],"award-info":[{"award-number":["U54CA118638"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute"},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R25GM058268"],"award-info":[{"award-number":["R25GM058268"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA118638"],"award-info":[{"award-number":["U54CA118638"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chronic Lymphocytic Leukemia Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Protein expression for 384 total and post-translationally modified proteins was assessed in 871 CLL and MSBL patients and was integrated with clinical data to identify strategies for improving diagnostics and therapy, making this the largest CLL proteomics study to date. Proteomics identified six recurrent signatures that were highly prognostic of survival and time to first or second treatment at three levels: individual proteins, when grouped into 40 functionally related groups (PFGs), and systemically in signatures (SGs). A novel SG characterized by hairy cell leukemia like proteomics but poor therapy response was discovered. SG membership superseded other prognostic factors (Rai Staging, IGHV Status) and were prognostic for response to modern (BTK inhibition) and older CLL therapies. SGs and PFGs membership provided novel drug targets and defined optimal candidates for Watch and Wait vs. early intervention. Collectively proteomics demonstrates promise for improving classification, therapeutic strategy selection, and identifying novel therapeutic targets.<\/jats:p>","DOI":"10.1038\/s41408-022-00623-7","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T08:05:19Z","timestamp":1647504319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4227-3870","authenticated-orcid":false,"given":"Ti\u2019ara L.","family":"Griffen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fieke W.","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James W.","family":"Lillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-6031","authenticated-orcid":false,"given":"Philip","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endurance","family":"Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6177-7572","authenticated-orcid":false,"given":"Jan","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7357-270X","authenticated-orcid":false,"given":"William","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-9548","authenticated-orcid":false,"given":"Steven M.","family":"Kornblau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"623_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"623_CR2","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","volume":"127","author":"F Nadeu","year":"2016","unstructured":"Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016;127:2122\u201330.","journal-title":"Blood"},{"key":"623_CR3","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.clml.2019.03.002","volume":"19","author":"A Visentin","year":"2019","unstructured":"Visentin A, Facco M, Gurrieri C, Pagnin E, Martini V, Imbergamo S, et al. Prognostic and predictive effect of IGHV mutational status and load in chronic lymphocytic leukemia: focus on FCR and BR treatments. Clin Lymphoma Myeloma Leuk. 2019;19:678\u201385. e4","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"623_CR4","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","volume":"94","author":"RN Damle","year":"1999","unstructured":"Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840\u20137.","journal-title":"Blood"},{"key":"623_CR5","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1038\/sj.leu.2403147","volume":"17","author":"J Durig","year":"2003","unstructured":"Durig J, Nuckel H, Cremer M, Fuhrer A, Halfmeyer K, Fandrey J, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia. 2003;17:2426\u201334.","journal-title":"Leukemia"},{"key":"623_CR6","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1038\/sj.leu.2404935","volume":"21","author":"C Haferlach","year":"2007","unstructured":"Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia. 2007;21:2442\u201351.","journal-title":"Leukemia"},{"key":"623_CR7","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1097\/HS9.0000000000000175","volume":"3","author":"DY Yosifov","year":"2019","unstructured":"Yosifov DY, Wolf C, Stilgenbauer S, Mertens D. From biology to therapy: the CLL success story. Hemasphere. 2019;3:e175.","journal-title":"Hemasphere"},{"key":"623_CR8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol. 2013;31:88\u201394.","journal-title":"J Clin Oncol"},{"key":"623_CR9","doi-asserted-by":"crossref","unstructured":"AACR. Venetoclax yields strong responses in CLL. Cancer Discov. 2016;6:113\u20134.","DOI":"10.1158\/2159-8290.CD-NB2015-180"},{"key":"623_CR10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl J Med. 2014;370:997\u20131007.","journal-title":"N. Engl J Med"},{"key":"623_CR11","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","volume":"132","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, Hillmen P, Montillo M, Nagy Z, Illes A, Etienne G, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood. 2018;132:2446\u201355.","journal-title":"Blood"},{"key":"623_CR12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood.2019003715","volume":"136","author":"C Sun","year":"2020","unstructured":"Sun C, Nierman P, Kendall EK, Cheung J, Gulrajani M, Herman SEM, et al. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. Blood. 2020;136:93\u2013105.","journal-title":"Blood"},{"key":"623_CR13","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N. Engl J Med. 2019;380:2095\u2013103.","journal-title":"N. Engl J Med"},{"key":"623_CR14","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","volume":"21","author":"O Al-Sawaf","year":"2020","unstructured":"Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21:1188\u2013200.","journal-title":"Lancet Oncol"},{"key":"623_CR15","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1074\/mcp.RA117.000425","volume":"17","author":"RL Mayer","year":"2018","unstructured":"Mayer RL, Schwarzmeier JD, Gerner MC, Bileck A, Mader JC, Meier-Menches SM, et al. Proteomics and metabolomics identify molecular mechanisms of aging potentially predisposing for chronic lymphocytic leukemia. Mol Cell Proteom. 2018;17:290\u2013303.","journal-title":"Mol Cell Proteom"},{"key":"623_CR16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bjh.15751","volume":"185","author":"LA Thurgood","year":"2019","unstructured":"Thurgood LA, Dwyer ES, Lower KM, Chataway TK, Kuss BJ. Altered expression of metabolic pathways in CLL detected by unlabelled quantitative mass spectrometry analysis. Br J Haematol. 2019;185:65\u201378.","journal-title":"Br J Haematol"},{"key":"623_CR17","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/10428194.2017.1376747","volume":"59","author":"HV Vangapandu","year":"2018","unstructured":"Vangapandu HV, Chen H, Wierda WG, Keating MJ, Korkut A, Gandhi V. Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma. 2018;59:1427\u201338.","journal-title":"Leuk Lymphoma"},{"key":"623_CR18","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.18632\/oncotarget.13712","volume":"8","author":"V Griggio","year":"2017","unstructured":"Griggio V, Mandili G, Vitale C, Capello M, Macor P, Serra S, et al. Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. Oncotarget. 2017;8:3274\u201388.","journal-title":"Oncotarget"},{"key":"623_CR19","doi-asserted-by":"crossref","unstructured":"Meier-Abt F, Lu J, Cannizzaro E, Pohly MF, Kummer S, Pfammatter S, et al. The protein landscape of chronic lymphocytic leukemia (CLL). Blood. 2021;138:2514\u201325.","DOI":"10.1182\/blood.2020009741"},{"key":"623_CR20","doi-asserted-by":"publisher","unstructured":"van Dijk AD, Griffen TL, Qiu YH, Hoff FW, Toro E, Ruiz K, et al. RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia. 2021. https:\/\/doi.org\/10.1038\/s41375-021-01438-4.","DOI":"10.1038\/s41375-021-01438-4"},{"key":"623_CR21","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1074\/mcp.RA117.000539","volume":"17","author":"HE Johnston","year":"2018","unstructured":"Johnston HE, Carter MJ, Larrayoz M, Clarke J, Garbis SD, Oscier D, et al. Proteomics profiling of CLL versus healthy B-cells identifies putative therapeutic targets and a subtype-independent signature of spliceosome dysregulation. Mol Cell Proteom. 2018;17:776\u201391.","journal-title":"Mol Cell Proteom"},{"key":"623_CR22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrg3185","volume":"13","author":"C Vogel","year":"2012","unstructured":"Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13:227\u201332.","journal-title":"Nat Rev Genet"},{"key":"623_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tibs.2014.10.010","volume":"40","author":"SH Payne","year":"2015","unstructured":"Payne SH. The utility of protein and mRNA correlation. Trends Biochem Sci. 2015;40:1\u20133.","journal-title":"Trends Biochem Sci"},{"key":"623_CR24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ccell.2018.12.003","volume":"35","author":"DG Mun","year":"2019","unstructured":"Mun DG, Bhin J, Kim S, Kim H, Jung JH, Jung Y, et al. Proteogenomic characterization of human early-onset gastric cancer. Cancer Cell. 2019;35:111\u201324. e10","journal-title":"Cancer Cell"},{"key":"623_CR25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature13438","volume":"513","author":"B Zhang","year":"2014","unstructured":"Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014;513:382\u20137.","journal-title":"Nature"},{"key":"623_CR26","first-page":"1937","volume":"15","author":"Z Xu","year":"2018","unstructured":"Xu Z, Xiong D, Zhang J, Zhang J, Chen X, Chen Z, et al. Bone marrow stromal cells enhance the survival of chronic lymphocytic leukemia cells by regulating HES-1 gene expression and H3K27me3 demethylation. Oncol Lett. 2018;15:1937\u201342.","journal-title":"Oncol Lett"},{"key":"623_CR27","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.525","volume":"6","author":"GS Choudhary","year":"2015","unstructured":"Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593.","journal-title":"Cell Death Dis"},{"key":"623_CR28","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1182\/blood-2011-07-367417","volume":"119","author":"A Paterson","year":"2012","unstructured":"Paterson A, Mockridge CI, Adams JE, Krysov S, Potter KN, Duncombe AS, et al. Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia. Blood. 2012;119:1726\u201336.","journal-title":"Blood"},{"key":"623_CR29","doi-asserted-by":"crossref","unstructured":"Marques-Piubelli ML, Schlette EJ, Khoury JD, Furqan F, Vega F, Soto LMS, et al. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. Leuk Lymphoma. 2021;62:1129\u201335.","DOI":"10.1080\/10428194.2020.1861278"},{"key":"623_CR30","doi-asserted-by":"crossref","unstructured":"Fadaka AO, Bakare OO, Sibuyi NRS, Klein A. Gene expression alterations and molecular analysis of CHEK1 in solid tumors. Cancers (Basel). 2020;12(3):662.","DOI":"10.3390\/cancers12030662"},{"key":"623_CR31","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccr.2010.08.011","volume":"18","author":"SE Mir","year":"2010","unstructured":"Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, Niers JM, et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell. 2010;18:244\u201357.","journal-title":"Cancer Cell"},{"key":"623_CR32","doi-asserted-by":"crossref","first-page":"e38254","DOI":"10.1371\/journal.pone.0038254","volume":"7","author":"GI Magnussen","year":"2012","unstructured":"Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A, Florenes VA. High expression of WEE1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS One. 2012;7:e38254.","journal-title":"PLoS One"},{"key":"623_CR33","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-13-147","volume":"13","author":"C Bryant","year":"2014","unstructured":"Bryant C, Scriven K, Massey AJ. Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human leukemia and lymphoma cells. Mol Cancer. 2014;13:147.","journal-title":"Mol Cancer"},{"key":"623_CR34","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","volume":"127","author":"M Kwok","year":"2016","unstructured":"Kwok M, Davies N, Agathanggelou A, Smith E, Oldreive C, Petermann E, et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood. 2016;127:582\u201395.","journal-title":"Blood"},{"key":"623_CR35","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.3324\/haematol.2018.203430","volume":"104","author":"M Boudny","year":"2019","unstructured":"Boudny M, Zemanova J, Khirsariya P, Borsky M, Verner J, Cerna J, et al. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. Haematologica. 2019;104:2443\u201355.","journal-title":"Haematologica"},{"key":"623_CR36","doi-asserted-by":"crossref","first-page":"62091","DOI":"10.18632\/oncotarget.11388","volume":"7","author":"J Zemanova","year":"2016","unstructured":"Zemanova J, Hylse O, Collakova J, Vesely P, Oltova A, Borsky M, et al. Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells. Oncotarget. 2016;7:62091\u2013106.","journal-title":"Oncotarget"},{"key":"623_CR37","first-page":"3159","volume":"12","author":"K Do","year":"2013","unstructured":"Do K, Doroshow JH, Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle. 2013;12:3159\u201364.","journal-title":"Cell Cycle"},{"key":"623_CR38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(18)30009-3","volume":"19","author":"JM Lee","year":"2018","unstructured":"Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, et al. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet Oncol. 2018;19:207\u201315.","journal-title":"Lancet Oncol"},{"key":"623_CR39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/10428190009089430","volume":"37","author":"M Hibi","year":"2000","unstructured":"Hibi M, Hirano T. Gab-family adapter molecules in signal transduction of cytokine and growth factor receptors, and T and B cell antigen receptors. Leuk Lymphoma. 2000;37:299\u2013307.","journal-title":"Leuk Lymphoma"},{"key":"623_CR40","first-page":"427","volume":"45","author":"LF Wei","year":"2021","unstructured":"Wei LF, Weng XF, Huang XC, Peng YH, Guo HP, Xu YW. IGFBP2 in cancer: pathological role and clinical significance (review). Oncol Rep. 2021;45:427\u201338.","journal-title":"Oncol Rep."},{"key":"623_CR41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/978-1-4939-9030-6_22","volume":"1929","author":"N Ambartsumian","year":"2019","unstructured":"Ambartsumian N, Klingelhofer J, Grigorian M. The multifaceted S100A4 protein in cancer and inflammation. Methods Mol Biol. 2019;1929:339\u201365.","journal-title":"Methods Mol Biol"},{"key":"623_CR42","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","volume":"101","author":"A Wiestner","year":"2003","unstructured":"Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944\u201351.","journal-title":"Blood"},{"key":"623_CR43","doi-asserted-by":"crossref","first-page":"595832","DOI":"10.3389\/fonc.2020.595832","volume":"10","author":"J Chen","year":"2020","unstructured":"Chen J, Moore A, Ringshausen I. ZAP-70 shapes the immune microenvironment in B cell malignancies. Front Oncol. 2020;10:595832.","journal-title":"Front Oncol"},{"key":"623_CR44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1084\/jem.20031175","volume":"199","author":"K Basso","year":"2004","unstructured":"Basso K, Liso A, Tiacci E, Benedetti R, Pulsoni A, Foa R, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med. 2004;199:59\u201368.","journal-title":"J Exp Med"},{"key":"623_CR45","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1158\/1541-7786.MCR-17-0731","volume":"16","author":"FW Hoff","year":"2018","unstructured":"Hoff FW, Hu CW, Qiu Y, Ligeralde A, Yoo SY, Mahmud H, et al. Recognition of recurrent protein expression patterns in pediatric acute myeloid leukemia identified new therapeutic targets. Mol Cancer Res. 2018;16:1275\u201386.","journal-title":"Mol Cancer Res"},{"key":"623_CR46","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/1535-7163.MCT-06-0334","volume":"5","author":"R Tibes","year":"2006","unstructured":"Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006;5:2512\u201321.","journal-title":"Mol Cancer Ther"},{"key":"623_CR47","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/bioinformatics\/btu736","volume":"31","author":"Z Ju","year":"2015","unstructured":"Ju Z, Liu W, Roebuck PL, Siwak DR, Zhang N, Lu Y, et al. Development of a robust classifier for quality control of reverse-phase protein arrays. Bioinformatics. 2015;31:912\u20138.","journal-title":"Bioinformatics"},{"key":"623_CR48","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/bioinformatics\/btp174","volume":"25","author":"ES Neeley","year":"2009","unstructured":"Neeley ES, Kornblau SM, Coombes KR, Baggerly KA. Variable slope normalization of reverse phase protein arrays. Bioinformatics. 2009;25:1384\u20139.","journal-title":"Bioinformatics"},{"key":"623_CR49","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41551-019-0387-2","volume":"3","author":"CW Hu","year":"2019","unstructured":"Hu CW, Qiu Y, Ligeralde A, Raybon AY, Yoo SY, Coombes KR, et al. A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia. Nat Biomed Eng. 2019;3:889\u2013901.","journal-title":"Nat Biomed Eng"},{"key":"623_CR50","doi-asserted-by":"crossref","first-page":"e1800133","DOI":"10.1002\/prca.201800133","volume":"13","author":"FW Hoff","year":"2019","unstructured":"Hoff FW, Hu CW, Qutub AA, Qiu Y, Hornbaker MJ, Bueso-Ramos C, et al. Proteomic profiling of acute promyelocytic leukemia identifies two protein signatures associated with relapse. Proteom Clin Appl. 2019;13:e1800133.","journal-title":"Proteom Clin Appl"},{"key":"623_CR51","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1158\/1541-7786.MCR-17-0730","volume":"16","author":"FW Hoff","year":"2018","unstructured":"Hoff FW, Hu CW, Qiu Y, Ligeralde A, Yoo SY, Scheurer ME, et al. Recurrent patterns of protein expression signatures in pediatric acute lymphoblastic leukemia: recognition and therapeutic guidance. Mol Cancer Res. 2018;16:1263\u201374.","journal-title":"Mol Cancer Res"},{"key":"623_CR52","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","volume":"17","author":"International CLLIPIwg.","year":"2016","unstructured":"International CLLIPIwg. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779\u201390.","journal-title":"Lancet Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00623-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00623-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00623-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T20:05:50Z","timestamp":1669233950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00623-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["623"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00623-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"19 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}